<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    <title>Official Site for KOKOWA®</title>
    <meta name="keywords" content=""/>
    <meta name="description" content=""/>
    <meta name="applicable-device" content="pc,mobile">
    <link href="../css/bootstrap.css" rel="stylesheet">
    <link href="../css/bxslider.css" rel="stylesheet">
    <link href="../css/style.css" rel="stylesheet">
    <script src="../js/jquery.min.js"></script>
    <script src="../js/bxslider.min.js"></script>
    <script src="../js/common.js"></script>
    <script src="../js/bootstrap.js"></script>
    <!--[if lt IE 9]>
    <script src="../js/html5shiv.min.js"></script>
    <script src="../js/respond.min.js"></script>
    <![endif]-->

</head>

<body>

<header>
    <div class="topBox">
        <div class="borderBottom">
            <div class="container">
                <div class="row">
                    <div class="welcomeBox">KOKOWA<sup>®</sup></div>

                    <div class="languageBox">
                        <a href="../cn/index-cn.html" class="zh">Chinese</a>
                        <a href="../en/index-en.html" class="en">English</a>
                        <a href="../jp/index-jp.html" class="jp">Japanese</a>
                    </div>
                    <div class="topContactBox">
                        <img src="../images/inf.png"/>
                        <a href="kokowaproduct-cautions-cn.html">Information</a>
                        <img src="../images/mail.png"/>
                        <a href="mailto:aa@aa.com">Doctor</a>
                    </div>
                </div>
            </div>
        </div>

    </div>

    <!-- Fixed navbar -->
    <nav class="navbar navbar-default navbar-fixed-top">
        <div class="container">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#navbar"
                        aria-expanded="false" aria-controls="navbar">
                    <span class="sr-only">Toggle navigation</span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
                <a href="index-en.html"><img src="../images/logo1.png" class="logo" alt="welcome~"/></a>

            </div>
            <div id="navbar" class="navbar-collapse collapse">
                <ul class="nav navbar-nav navbar-nav-c">
                    <li class="dropdown">
                        <a href="aboutWT1-en.html">About WT1</a>
                        <a href="javascript:;" id="app_menudown" class="dropdown-toggle" data-toggle="dropdown"
                           role="button" aria-expanded="false"><span
                                class="glyphicon glyphicon-menu-down btn-xs"></span></a>
                        <ul class="dropdown-menu nav_small" role="menu">
                            <li><a href="aboutWT1-en-whatswt1.html">What's WT1?</a></li>
                            <li><a href="vaccineAdaptedCancer-en.html">Identification of Human WT1 Protein-derived
                                CTL(HLA CLASS I)
                                and HELPER(CLASS II) Epitopes</a></li>
                            <li><a href="principleOfWT1-en.html">The principle of WT1 as a tumor suppressor antigen</a>
                            </li>
                        </ul>
                    </li>

                    <li class="dropdown">
                        <a href="kokowa-en.html">About KOKOWA<sup>®</sup></a>
                        <a href="javascript:;" id="app_menudown" class="dropdown-toggle" data-toggle="dropdown"
                           role="button" aria-expanded="false"><span
                                class="glyphicon glyphicon-menu-down btn-xs"></span></a>
                        <ul class="dropdown-menu nav_small" role="menu">
                            <li><a href="kokowa-en.html">What's KOKOWA<sup>®</sup></a></li>
                            <li><a href="kokowaproduct-en.html">KOKOWA<sup>®</sup> Product Description</a></li>
                        </ul>
                    </li>
                    <li class="dropdown">
                        <a href="javascript:;">What should we do?</a>
                        <a href="javascript:;" id="app_menudown" class="dropdown-toggle" data-toggle="dropdown"
                           role="button" aria-expanded="false"><span
                                class="glyphicon glyphicon-menu-down btn-xs"></span></a>
                        <ul class="dropdown-menu nav_small" role="menu">
                            <li><a href="">Talk to your Doctor</a></li>
                        </ul>
                    </li>
                    <li class="dropdown">
                        <a href="javascript:;">Access and support</a>
                        <a href="javascript:;" id="app_menudown" class="dropdown-toggle" data-toggle="dropdown"
                           role="button" aria-expanded="false"><span
                                class="glyphicon glyphicon-menu-down btn-xs"></span></a>
                        <ul class="dropdown-menu nav_small" role="menu">
                            <li><a href="moreProfessionalQuestion-en.html">More Professional Questions</a></li>
                        </ul>
                    </li>

                </ul>

            </div><!--/.nav-collapse -->
        </div>
    </nav>
</header>

<!-- bxslider -->
<div class="flash">
    <img src="../images/kokowa-wt1-en-1.png" alt=""/>
</div>



<!--div class="page_bg" style="background: url(../images/smal-banner-jp.png) center top no-repeat;">
</div-->

<div class="container threeImgBox">
    <div class="row">
        <div class="index_wt1">
            <h2>IDENTIFICATION OF HUMAN WT1 PROTEIN-DERIVED CTL (HLA CLASS I) AND HELPER (CLASS II) EPITOPES</h2>
            <ul>
            <li>
                <a target=_blank href="vaccineAdaptedCancer-en-1.html">GLIOBLASTOMA MULTIFORME</a>
                <a target=_blank href="vaccineAdaptedCancer-en-2.html">MULTIPLE MYELOMA</a>
                <a target=_blank href="vaccineAdaptedCancer-en-3.html">LUNG CANCER</a>
                <a target=_blank href="vaccineAdaptedCancer-en-4.html">CHRONIC MYELOMONOCYTIC LEUKEMIA</a>
                <a target=_blank href="vaccineAdaptedCancer-en-5.html">BREAST CANCER</a>
                <a target=_blank href="">...</a>
            </li>
            </ul>
        </div>

    </div>
</div>

<div class="container" style="border-bottom:1px dashed #000;">
    <div class="col-xs-12 col-sm-8 col-md-7">
        <div class="news_box">
            <h2 class="title_h2"><a href="vaccineAdaptedCancer-en-1.html">GLIOBLASTOMA MULTIFORME</a> </h2>

            <ul class="index_news">
                <p class="content">
                    WT1 vaccine was administered to 23 HLA-A*2404-positive patients with recurrent glioblastoma multiforme that was resistant to standard therapies (77). The only adverse effect was again local erythema at the WT1 vaccine injection sites. Clinical response according to RECIST criteria was partial response in 2 patients (Fig. 5), stable disease (SD) in 10 patients and progressive disease in 9 patients. Overall response and disease control rates were 9.5% and 57.1%, respectively. Median progression-free survival (PFS) time and 6-month PFS rate were 20.0 weeks and 33.3%, respectively. For two SD patients, long-term SD of more than 236 and 184 weeks, respectively, with only skin erythema at the WT1 vaccine injection sites has continued until the time of writing.
                    ...
                </p>
                <a href="vaccineAdaptedCancer-en-1.html" class="service-all">more</a>
            </ul>
        </div>
    </div>

    <div class="col-xs-12 col-sm-4 col-md-5">
        <div class="index_contact">
            <h2 class="title_h2"></h2>
            <ul class="index_news">
                <img src="../images/chapter10.f2.jpg" alt=""/>
            </ul>
        </div>
    </div>
</div>

<div class="container" style="border-bottom:1px dashed #000;background:#ffe; filter: Alpha(Opacity=10, Style=0);">
    <div class="col-xs-12 col-sm-4 col-md-5">
        <div class="index_contact">
            <h2 class="title_h2"><a href="vaccineAdaptedCancer-en-2.html">MULTIPLE MYELOMA</a></h2>
            <ul class="index_news">
                <img src="../images/images02.jpeg" alt="MULTIPLE MYELOMA">
            </ul>
        </div>
    </div>

    <div class="col-xs-12 col-sm-8 col-md-7">
        <div class="news_box">
            <h2 class="title_h2">&nbsp; </h2>
            <ul class="index_news">
                <p class="content">
                    Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1-specific CTLs (79). A HLAA* 2402-positive patient with advanced therapy-resistant multiple myeloma was treated with WT1 vaccine (Figs 6 and 7) (80). Myeloma cells in BM decreased from 85% to 25%, andthe amount of M protein in the urine decreased from 3.6 to 0.6 g/day after the WT1 vaccination. A bone centigram showed improvement of bone lesions, especially of the ribs, so that the clinical response was assessed as minimal (EGBMT criteria).
                </p>
                <a href="vaccineAdaptedCancer-en-2.html" class="service-all">more</a>
            </ul>
        </div>
    </div>

</div>



</div>

<div class="container" style="border-bottom:1px dashed #000;">
    <div class="col-xs-12 col-sm-8 col-md-7">
        <div class="news_box">
            <h2 class="title_h2"><a href="vaccineAdaptedCancer-en-3.html">LUNG CANCER</a> </h2>

            <ul class="index_news">
                <p class="content">
                    Tsuboi et al. (74) reported that two patients with advanced lung cancer were WT1-vaccinated with 0.3 mg of an HLA-A*2402-restricted WT1 peptide at 2-week intervals, resulting in a reduction in tumor markers such as chorio-embryonic antigen and tumor size.
                    Oji et al. (90) analyzed WT1 IgG antibodies in patients with non-small cell lung cancer (NSCLC) and reported that pre-operative elevation of WT1 antibodies was significantly associated with longer diseasefree survival in NSCLC patients with Stages I–III, which suggests that WT1-specific immune response has an important role in anticancer immunity (Fig. 9).
                    ...
                </p>
            </ul>
            <a href="vaccineAdaptedCancer-en-3.html" class="service-all">more</a>
        </div>
    </div>

    <div class="col-xs-12 col-sm-4 col-md-5">
        <div class="index_contact">
            <h2 class="title_h2"></h2>
            <ul class="index_news">
                <img src="../images/GettyImages-636177454.png" alt=""/>
            </ul>
        </div>
    </div>
</div>

<div class="container" style="border-bottom:1px dashed #000;background:#eee; filter: Alpha(Opacity=10, Style=0);">

    <div class="col-xs-12 col-sm-8 col-md-7">
        <div class="news_box">
            <h2 class="title_h2"><a href="vaccineAdaptedCancer-en-4.html">CHRONIC MYELOMONOCYTIC LEUKEMIA</a> </h2>

            <ul class="index_news">
                <p>
                    MDS, which is a stem cell leukemia, was very sensitive to WT1 peptide vaccination, so that vaccination with the usual dose of WT1 peptide proved to be dangerous because of the rapid reduction in leukocytes derived from WT1-expressing transformed leukemic hematopoietic cells (72). Therefore, a new Phase I study, in which the WT1 peptide dose started from 5 mg/body and reached a maximum of 50 through 15 mg/ body, was started in 2005. A 57-year-old male patient with chronic myelomonocytic leukemia was vaccinated biweekly with a very low dose of 5 mg/body of modified WT1 peptide (Fig. 8) (86). After the WT1 peptide vaccination, leukocyte and monocyte counts (13 780 and 1930/mL, respectively) gradually decreased to normal range in association with an increase in WT1-specific CTLs. This case demonstrated for the first time that vaccination with as little as 5 mg/body of WT1 peptide could induce WT1-specific immune response and the resultant clinical effect.
                    ...
                </p>
            </ul>
            <a href="vaccineAdaptedCancer-en-4.html" class="service-all">more</a>
        </div>
    </div>

    <div class="col-xs-12 col-sm-4 col-md-5">
        <div class="index_contact">
            <h2 class="title_h2"></h2>
            <ul class="index_news">
                <image src="../images/chronic-myelogenous-leukemia-cml-[5-bm099-3].png"/>
            </ul>
        </div>
    </div>

</div>

<div class="container" style="border-bottom:1px dashed #000;">
    <div class="col-xs-12 col-sm-8 col-md-7">
        <div class="news_box">
            <h2 class="title_h2"><a href="vaccineAdaptedCancer-en-5.html">BREAST CANCER</a></h2>

            <ul class="index_news">
                <p class="content">
                    Gillmore et al. (84) analyzed paired tumor-draining lymph nodes and peripheral blood samples from five HLA-A2-positive patients with Stage I/II breast cancer to quantify WT1-specific CTLs. WT1 tetramer-binding T cells expanded from all lymph node samples but from none of the corresponding peripheral blood samples. This finding demonstrated that WT1-specific CTLs could expand from the tumor-draining lymph nodes of breast cancer patients and perform a peptide-specific effector function.
                    Oka et al. (72) reported that two patients with advanced breast cancer were treated with 0.3 mg of modified WT1 peptide or 1.0 mg of natural WT1 peptide, respectively, and that both patients showed the regression of metastatic tumors. The latter patient’s disease was progressive with ileus due to metastatic tumors in colon before WT1 vaccination. After the second WT1 vaccination, a computed tomographic scan showed that thickening of the walls of the colon tract had significantly improved, accompanied by improved appetite, and the patient survived for 3 years and 1 month after WT1 vaccination....
                </p>
            </ul>
            <a href="vaccineAdaptedCancer-en-5.html" class="service-all">more</a>
        </div>
    </div>

    <div class="col-xs-12 col-sm-4 col-md-5">
        <div class="index_contact">
            <h2 class="title_h2"></h2>
            <ul class="index_news">
                <img src="../images/IndianJMedRes_2013_137_1_57_108271_f2.png" alt=""/>
            </ul>
        </div>
    </div>
</div>

<footer>
    <div class="copyright">
        <p>
            <a href="faq-en.html" target="_blank">&nbsp;&nbsp;FAQ&nbsp;&nbsp;</a> |
            <a href="moreProfessionalQuestion-en.html" target="_blank">&nbsp;&nbsp;More Professional Questions&nbsp;&nbsp;</a> |
            <a href="sitemap-en.html" target="_blank">&nbsp;&nbsp;Site Map</a>
        </p>
        <p>CopyRight© 2018 All Right Reserved KOKOWA<sup>®</sup> & Japan Cancer Institute Corporation &nbsp;
        </p>
    </div>

</footer>

</body>
</html>
